PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement
2024

Study on LB-102: A New Antipsychotic Drug

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): Wong Dean F., Chand Ganesh B., Caito Nicole, Eramo Anna, Grattan Vincent T., Hixon Mark S., Nicol Ginger, Lessie Erin, Prensky Zachary, Kuwabara Hiroto, Tian Lucy, Valenta Ines, Schindler Thomas H., GrĂ¼nder Gerhard, Vaino Andrew R.

Primary Institution: Mallinckrodt Institute of Radiology, Washington University in Saint Louis

Hypothesis

The study aimed to measure the dopamine receptor occupancy of orally administered LB-102 at different doses and timepoints in healthy volunteers.

Conclusion

LB-102 demonstrated prolonged dopamine receptor occupancy, suggesting it could be effective in treating schizophrenia.

Supporting Evidence

  • LB-102 provided approximately 70% dopamine receptor occupancy, similar to higher doses of amisulpride.
  • The study showed that LB-102 was generally safe and well-tolerated at all doses.
  • Participants did not experience significant side effects typically associated with antipsychotics.

Takeaway

LB-102 is a new medicine that helps the brain work better for people with schizophrenia, and it stays effective for a long time after taking it.

Methodology

The study used positron emission tomography (PET) to measure dopamine receptor occupancy in healthy volunteers after administering different doses of LB-102.

Limitations

The study had a small number of receptor occupancy observations at steady state.

Participant Demographics

16 healthy volunteers (7 female, 9 male) aged 18 to 55 years with a BMI between 18 and 30 kg/m2.

Digital Object Identifier (DOI)

10.1038/s41386-024-01951-x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication